PMID- 19361406
OWN - NLM
STAT- MEDLINE
DCOM- 20090728
LR  - 20181201
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 25 Spec No 1
DP  - 2009 Mar
TI  - [Biological criteria of eligibility for a treatment against EGFR].
PG  - 21-4
LID - 10.1051/medsci/2009251s21 [doi]
AB  - The proteasome plays a pivotal role in the turnover of regulatory transduction 
      proteins induced by activated cell membrane growth factor receptors. The 
      epidermal growth factor receptor (EGFR) pathway is crucial in the development and 
      progression of human epithelial cancers. The combined treatment with EGFR 
      inhibitors has a synergistic growth inhibitory and pro-apoptotic activity in 
      different human cancer cells which possess a functional EGFR-dependent autocrine 
      growth pathway through to a more efficient and sustained inhibition of Akt. But 
      resistance has been observed in case of KRAS mutation. Inhibition of a single 
      transduction pathway is often inefficient due to activation of alternative 
      signalling. The mammalian target of rapamycin (mTOR) is a key intracellular 
      kinase integrating proliferation, survival and angiogenic pathways and has been 
      implicated in the resistance to EGFR inhibitors. Thus, mTOR blockade is pursued 
      to interfere at multiple levels with tumour growth. Targeting mTOR pathway 
      overcomes resistance to EGFR inhibitors and produces a cooperative effect with 
      EGFR inhibitors, providing a valid therapeutic strategy to be tested in a 
      clinical setting.
FAU - Laurent-Puig, Pierre
AU  - Laurent-Puig P
AD  - Inserm UMR-S775, Bases moleculaires de la reponse aux xenobiotiques, Laboratoire 
      de Toxicologie Moleculaire, 45, rue des Saints- Peres, 75006 Paris, France. 
      pierre.laurent-puig@univ-paris5.fr
LA  - fre
PT  - Journal Article
TT  - Criteres biologiques d'eligibilite pour un traitement anti-EGFR.
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (KRAS protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 6A901E312A (Panitumumab)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Mutation
MH  - Neoplasms/*drug therapy/genetics
MH  - Panitumumab
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Proto-Oncogene Proteins p21(ras)
MH  - ras Proteins/genetics
EDAT- 2009/04/14 09:00
MHDA- 2009/07/29 09:00
CRDT- 2009/04/14 09:00
PHST- 2009/04/14 09:00 [entrez]
PHST- 2009/04/14 09:00 [pubmed]
PHST- 2009/07/29 09:00 [medline]
AID - 00/00/0D/76/ [pii]
AID - 10.1051/medsci/2009251s21 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2009 Mar;25 Spec No 1:21-4. doi: 10.1051/medsci/2009251s21.